Human pharmacokinetics of dihydroergotamine administered by nasal spray

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 3, 1996, Pages 265-275

  Humbert, Henri ^a,b   Cabiac, Marie Danièle ^a   Dubray, Claude ^a   Lavène, Danièle ^a  

^a Research Centre   (France)

^b Laboratoires Sandoz   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROERGOTAMINE; FENOXAZOLINE;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; KIDNEY CLEARANCE; MIGRAINE; NOSE MUCOSA; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

ACUTE DISEASE; ADMINISTRATION, INTRANASAL; ADULT; ANALGESICS, NON-NARCOTIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DIHYDROERGOTAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; LINEAR MODELS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; REFERENCE VALUES; RHINITIS;

EID: 0029812218     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90053-3     Document Type: Article

References (26)

1. Thulesius O, Berlin E. Dihydroergotamine therapy in orthostatic hypotension due to psychotropic drugs. Int J Clin Pharmacol Ther Toxicol 1986;24:465-7.
2. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine. Headache 1986;26:168-71.
3. Bobik A, Jennings G, Skews H, Esler M, McLean A. Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. Clin Pharmacol Ther 1981;30:673-9.
4. Little PJ, Jennings GL, Skews H, Bobik A. Bioavailability of dihydroergotamine in man. Br J Clin Pharmacol 1982;13:785-90.
5. Aellig WH. Investigation of the venoconstrictor effect of 8′-hydroxydihydroergotamine, the main metabolite of dihydroergotamine, in man. Eur J Clin Pharmacol 1984;26:239-42.
6. Müller-Schweinitzer E. Pharmacological action of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol 1984;26:699-705.
7. Kiechel JR. The bioavailability and kinetics of dihydroergotamine. In: Fitscha P, editor. Neuester Stand der Dihydergot-Forschung. Stuttgart: Georg Thieme, 1984:32-46.
8. Mondell B, DiSerio F, Friedman A. Dihydroergotamine nasal spray in the acute treatment of migraine headache [abstract]. Clin Pharmacol Ther 1989;45:161.
9. Massiou H. Dihydroergotamine nasal spray in prevention and treatment of migraine attacks: two controlled trials versus placebo. Cephalalgia 1987;7(suppl 6):440-1.
10. Rapoport A, Sheftell F, Couch J, Byer J, Markley H, Ford R, et al. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache 1995;35:177-84.
11. Gallagher RM, DiSerio F. Dihydroergotamine nasal spray in the acute treatment of migraine headache [abstract]. Clin Pharmacol Ther 1993;53:225.
12. Acezat-Mispelter F, Souchet T, Le Bigot JF, Guilmont B, Dubray C. Evaluation of nasal tolerability of dihydroergotamine via the nasal route. Cephalalgia 1987;7(suppl 6):422-3.
13. Souchet T, Dubray C, Acezat-Mispelter F, Guilmont B, Kiechel JR. Local tolerability evaluation of a drug administered by nasal route: application to dihydroergotamine. Presented at the International Society for Aerosols in Medicine, Vichy, France, October 2-4, 1986:75-84.
14. Le Bigot JF, Chevance LG, Humbert H, Rouaud JL, Taupin PJY, Thompson C. Dihydroergotamine (DHE) - a toxicological and pharmacokinetic study in cynomolgus monkeys following administration by intranasal route. Arch Toxicol 1986;59(suppl 9):472.
15. Aellig WH, Rosenthaler J. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration. Eur J Clin Pharmacol 1986;30:581-4.
16. Dubray C, Humbert H, Wurm M. Effect of dihydroergotamine of the venous tone study of the dose/ response relationship after administration by nasal route. Presented at the International Symposium on Measurement and Kinetics of in vivo Drug Effects, IUPHAR Satellite Symposium, Noordwijk, The Netherlands, June 28-30, 1990.
17. Schmidt R, Fanchamps A. Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol 1974;7:213-6.
18. 3H-labelled ligand as tracer for specific antibody and means to overcome experienced pitfalls. Int J Nucl Med Biol 1984;11:85-9.
19. Kleimola TT. Quantitative determination of ergot alkaloids in biological fluids by radioimmunoassay. Br J Clin Pharmacol 1978;6:255-60.
20. Luccioni F, Kiechel JR. Biodisponibilité comparée de deux formes orales de dihydroergotamine. Therapie 1979;34:625-34.
21. Gomeni R. PHARM: an interactive graphic program for individual and population pharmacokinetic parameter estimation. Comput Biol Med 1984;14:25-34.
22. Albert KS, Smith RB. Bioavailability assessment as influenced by variation in drug absorption. In: Albert KS, editor. Drug absorption and disposition: statistical considerations. Washington: American Pharmaceutical Association, 1980:87-113.
23. Passing H, Bablock W. A new biometral procedure for testing the equality of measurements from two different analytical methods. J Clin Chem Clin Biochem 1983;21:709-20.
24. Aellig WH, Nüesch E. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol Ther Toxicol 1977;15:106-12.
25. Schran HF, Tsé FLS. Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. Int J Clin Pharmacol Ther Toxicol 1985;23:1-4.
26. Humbert H, Lavène D, Guillaume MF, Kiechel JR. Pharmacocinétique de deux dérivés ergotés: la dihydroergotoxine et la dihydroergotamine. Biodisponibilité comparative de différentes formulations par rapport aux formes solutions. Premier Congrès Européen de Biopharmacie et Pharmacocinétique, Clermont-Ferrand, France, April 1-3, 1981, Editions Technique et Documentation, Paris, vol 1:334-40.